{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:53:31Z","timestamp":1777416811241,"version":"3.51.4"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Etrasimod is an oral, once daily, selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). This post hoc analysis of the ELEVATE UC clinical program describes etrasimod efficacy and safety by patients\u2019 baseline disease activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Predefined efficacy endpoints were assessed at week 12 in patients with moderately (modified Mayo score [MMS] 5\u20137) or severely (MMS 8\u20139) active UC using pooled data from ELEVATE UC 52 and ELEVATE UC 12. Descriptive statistics with 95% CI were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 743 patients analyzed, 525 (70.7%) had moderately active and 218 (29.3%) had severely active disease at baseline. At week 12, patients treated with etrasimod showed larger mean percentage reductions (95% CI) in MMS vs placebo, regardless of baseline disease activity (\u221248.4% [\u221252.3, \u221244.4] vs \u221227.0% [\u221232.2, \u221221.7] for moderately active disease and \u221246.4% [\u221251.2, \u221241.5] vs \u221229.8% [\u221237.2, \u221222.3] for severely active disease). Similar proportions of patients with moderately or severely active disease treated with etrasimod vs placebo achieved clinical response at week 12 (61.3% vs 39.8% for moderately active disease and 64.5% vs 30.3% for severely active disease). Incidence of treatment-emergent adverse events were similar between disease activity subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>At week 12, etrasimod showed greater reductions in disease activity and higher rates of clinical response vs placebo in patients with either moderately or severely active disease at baseline. The safety profile of etrasimod was consistent with the overall trial population and was unimpacted by baseline disease activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>ClinicalTrials.gov<\/jats:title>\n                    <jats:p>NCT03945188; NCT03996369.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izaf036","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T23:22:23Z","timestamp":1739229743000},"page":"2681-2692","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5762-5042","authenticated-orcid":false,"given":"Bruce E","family":"Sands","sequence":"first","affiliation":[{"name":"Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai , New York, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marla C","family":"Dubinsky","sequence":"additional","affiliation":[{"name":"Susan and Leonard Feinstein IBD Center, Icahn School of Medicine at Mount Sinai , New York, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo G","family":"Kotze","sequence":"additional","affiliation":[{"name":"IBD Outpatient Clinics, Colorectal Surgery Unit, Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1 (PUCPR) , Curitiba ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9verine","family":"Vermeire","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospitals Leuven , Leuven ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5247-940X","authenticated-orcid":false,"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary , Calgary, AB ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Millie D","family":"Long","sequence":"additional","affiliation":[{"name":"Center for Gastrointestinal Biology and Disease, University of North Carolina , Chapel Hill, NC ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C","family":"Woolcott","sequence":"additional","affiliation":[{"name":"Pfizer Inc , Collegeville, PA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Wu","sequence":"additional","affiliation":[{"name":"Pfizer Inc , Cambridge, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aoibhinn","family":"McDonnell","sequence":"additional","affiliation":[{"name":"Pfizer Ltd , Sandwich ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Goetsch","sequence":"additional","affiliation":[{"name":"Pfizer AG , Z\u00fcrich ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eustratios","family":"Bananis","sequence":"additional","affiliation":[{"name":"Pfizer Inc , Collegeville, PA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2293-5555","authenticated-orcid":false,"given":"Andres J","family":"Yarur","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center and Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center , Los Angeles, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"issue":"10080","key":"2025102715480712100_CIT0001","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet."},{"issue":"3","key":"2025102715480712100_CIT0002","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol."},{"issue":"9","key":"2025102715480712100_CIT0003","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol."},{"issue":"7","key":"2025102715480712100_CIT0004","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: Current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohns Colitis."},{"issue":"4","key":"2025102715480712100_CIT0005","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.gtc.2020.08.003","article-title":"Assessing severity of disease in patients with ulcerative colitis","volume":"49","author":"Pabla","year":"2020","journal-title":"Gastroenterol Clin North Am."},{"issue":"1","key":"2025102715480712100_CIT0006","doi-asserted-by":"publisher","first-page":"otab007","DOI":"10.1093\/crocol\/otab007","article-title":"Full, partial, and modified permutations of the Mayo Score: characterizing clinical and patient-reported outcomes in ulcerative colitis patients","volume":"3","author":"Naegeli","year":"2021","journal-title":"Crohns Colitis 360."},{"key":"2025102715480712100_CIT0007","author":"U.S. Department of Health & Human Services","journal-title":"Ulcerative colitis: clinical trial endpoints. Guidance for industry"},{"key":"2025102715480712100_CIT0008","author":"US Food and Drug Administration"},{"key":"2025102715480712100_CIT0009","author":"European Medicines Agency"},{"issue":"4","key":"2025102715480712100_CIT0010","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/14712598.2020.1697227","article-title":"Anti-interleukin-23 agents for the treatment of ulcerative colitis","volume":"20","author":"Han\u017eel","year":"2020","journal-title":"Expert Opin Biol Ther."},{"issue":"5","key":"2025102715480712100_CIT0011","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMc1707500","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"377","author":"Sandborn","year":"2017","journal-title":"N Engl J Med."},{"issue":"10383","key":"2025102715480712100_CIT0012","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet."},{"issue":"13","key":"2025102715480712100_CIT0013","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med."},{"issue":"6","key":"2025102715480712100_CIT0014","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.cgh.2020.01.017","article-title":"Positioning therapies in ulcerative colitis","volume":"18","author":"Danese","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"5","key":"2025102715480712100_CIT0015","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"issue":"3","key":"2025102715480712100_CIT0016","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/ecco-jcc\/jjac141","article-title":"Tofacitinib for the treatment of ulcerative colitis: an integrated summary of up to 7.8 years of safety data from the global clinical programme","volume":"17","author":"Sandborn","year":"2023","journal-title":"J Crohns Colitis."},{"issue":"3","key":"2025102715480712100_CIT0017","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/s0169-2607(97)01809-9","article-title":"A SAS macro for constructing simultaneous confidence intervals for multinomial proportions","volume":"53","author":"May","year":"1997","journal-title":"Comput Methods Programs Biomed."},{"issue":"2","key":"2025102715480712100_CIT0018","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1093\/ecco-jcc\/jjad146","article-title":"Efficacy and safety of approximately 3 years of continuous ozanimod in moderately to severely active ulcerative colitis: interim analysis of the True North open-label extension","volume":"18","author":"Danese","year":"2024","journal-title":"J Crohns Colitis."},{"issue":"9","key":"2025102715480712100_CIT0019","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.7326\/M22-1460","article-title":"Good Publication Practice (GPP) guidelines for company-sponsored biomedical research: 2022 update","volume":"175","author":"DeTora","year":"2022","journal-title":"Ann Intern Med."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izaf036\/62205969\/izaf036.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/10\/2681\/62205969\/izaf036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/10\/2681\/62205969\/izaf036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:48:15Z","timestamp":1761594495000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/10\/2681\/8046180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":19,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,2,28]]},"published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf036","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,2,28]]}}}